Linda Popplewell

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Maria Kinali, Virginia Arechavala‐Gomeza, Lucy Feng et al. · The Lancet Neurology · 2009 · 635 citations · Full text

Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle

Virginia Arechavala‐Gomeza, Ian R. Graham, Linda Popplewell et al. · Human Gene Therapy · 2007 · 149 citations

Exon Skipping, Antisense Oligonucleotide Sequences, Duchenne Muscular Dystrophy +11

Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice

Taeyoung Koo, Linda Popplewell, Takis Athanasopoulos et al. · Human Gene Therapy · 2013 · 99 citations

Viral Replication, Engineering, Coding Sequence +22

Antisense targeting of 3′ end elements involved in<i>DUX4</i>mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach

Anne-Charlotte Marsollier, Lukasz Ciszewski, Virginie Mariot et al. · Human Molecular Genetics · 2016 · 86 citations · Full text

Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene

Linda Popplewell, Capucine Trollet, George Dickson et al. · Molecular Therapy · 2009 · 80 citations · Full text